The truth about Tamiflu? Zanamivir should be inhaled, not nebulised
- PMID: 20071426
- PMCID: PMC3234150
- DOI: 10.1136/bmj.c131
The truth about Tamiflu? Zanamivir should be inhaled, not nebulised
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.BMJ. 2009 Dec 8;339:b5106. doi: 10.1136/bmj.b5106. BMJ. 2009. PMID: 19995812 Free PMC article.
References
-
- Relenza. Highlights of prescribing information (package insert). Available at: http://us.gsk.com/products/assets/us_relenza.pdf (Accessed 9 December 2009.)
-
- Summary of the product characteristics. www.lakemedelsverket.se/SPC_PIL/Pdf/enhumspc/Relenza%20inhalation%20powd... (Accessed 9 December 2009.)
-
- US Food and Drug Administration. Relenza (zanamivir) inhalation powder. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedica... (Accessed 9 December 2009.)
-
- FDA Safety. Important drug warning. Subject: Relenza (zanamivir) inhalation powder must not be nebulised. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforH... (Accessed 9 December 2009.)
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources